Edwards lifts 2026 sales growth outlook to 10%-11% while reaffirming $2.95-$3.05 EPS

EarningsPositive

AI Analysis

Summary

Edwards Lifesciences raised its 2026 sales growth outlook to 10%-11% while reaffirming EPS guidance of $2.95-$3.05. This represents an increase in confidence in the company's near-term financial performance.

Financial Highlights

EPS

$2.95-$3.05

Guidance

2026 sales growth outlook raised to 10%-11%

Importance:5/10

Sentiment:

0.60

guidanceearningssales growthEPS2026

Related Companies

$EW

Read the original article

Published by Seeking Alpha Healthcare on July 24, 2026 12:31 AM

Read Original